JP2019537608A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537608A5
JP2019537608A5 JP2019524973A JP2019524973A JP2019537608A5 JP 2019537608 A5 JP2019537608 A5 JP 2019537608A5 JP 2019524973 A JP2019524973 A JP 2019524973A JP 2019524973 A JP2019524973 A JP 2019524973A JP 2019537608 A5 JP2019537608 A5 JP 2019537608A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537608A (ja
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed filed Critical
Priority claimed from PCT/US2017/061682 external-priority patent/WO2018093820A1/en
Publication of JP2019537608A publication Critical patent/JP2019537608A/ja
Publication of JP2019537608A5 publication Critical patent/JP2019537608A5/ja
Priority to JP2022184577A priority Critical patent/JP2023018029A/ja
Pending legal-status Critical Current

Links

JP2019524973A 2016-11-15 2017-11-15 癌の処置のための医薬組成物および方法 Pending JP2019537608A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184577A JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/351,966 2016-11-15
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184577A Division JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Publications (2)

Publication Number Publication Date
JP2019537608A JP2019537608A (ja) 2019-12-26
JP2019537608A5 true JP2019537608A5 (OSRAM) 2020-12-24

Family

ID=60570232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524973A Pending JP2019537608A (ja) 2016-11-15 2017-11-15 癌の処置のための医薬組成物および方法
JP2022184577A Withdrawn JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184577A Withdrawn JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Country Status (12)

Country Link
EP (1) EP3541411A1 (OSRAM)
JP (2) JP2019537608A (OSRAM)
KR (2) KR20230003314A (OSRAM)
CN (1) CN110167580A (OSRAM)
AU (1) AU2017361080A1 (OSRAM)
BR (1) BR112019009799A2 (OSRAM)
CA (1) CA3040922A1 (OSRAM)
EA (1) EA201991192A1 (OSRAM)
IL (1) IL266486A (OSRAM)
MX (1) MX2019005450A (OSRAM)
PH (1) PH12019500758A1 (OSRAM)
WO (1) WO2018093820A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
EP4045027A1 (en) * 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4255920A4 (en) * 2020-12-02 2024-10-23 Hoffman Technologies LLC COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Similar Documents

Publication Publication Date Title
JP2019537608A5 (OSRAM)
Zheng et al. Tumor-associated neutrophils in colorectal cancer development, progression and immunotherapy
Chen et al. Leukotriene A4 hydrolase as a target for cancer prevention and therapy
JP2019508443A5 (OSRAM)
JP2009242409A5 (OSRAM)
JP2019516709A5 (OSRAM)
JP2017513836A5 (OSRAM)
JP2019513694A5 (OSRAM)
JP2004513076A5 (OSRAM)
JP2003523336A5 (OSRAM)
JP2017505285A5 (OSRAM)
Palkar et al. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-β/δ antagonist GSK3787
JP2004504347A5 (OSRAM)
JP2009530398A5 (OSRAM)
RU2018134336A (ru) Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
JP2014527083A5 (OSRAM)
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
Tavares et al. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment
PE20091213A1 (es) Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico
JP2011046708A5 (OSRAM)
JP5312026B2 (ja) Ppar受容体及びegf受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用
JP2009502777A5 (OSRAM)
JP2013533212A5 (OSRAM)
RU2008131311A (ru) Производные тритерпенхинона и тритерпенфенола и их применение для лечения опухолей и паразитарных заболеваний